The impact of osimertinib'line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

V Fuchs, L Roisman, W Kian, L Daniel, J Dudnik… - Lung Cancer, 2021 - Elsevier
Background Resistance mechanisms following 1st line therapy with osimertinib in EGFR+
NSCLC have become focus of investigation. This retrospective study aims to deepen the …
被引用次数：21 相关文章

The impact of osimertinib'line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

V Fuchs, L Roisman, W Kian, L Daniel… - Lung …, 2021 - lungcancerjournal.info
Background Resistance mechanisms following 1st line therapy with osimertinib in EGFR+
NSCLC have become focus of investigation. This retrospective study aims to deepen the …

The impact of osimertinib'line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

V Fuchs, L Roisman, W Kian… - Lung cancer …, 2021 - pubmed.ncbi.nlm.nih.gov
Background Resistance mechanisms following 1st line therapy with osimertinib in EGFR+
NSCLC have become focus of investigation. This retrospective study aims to deepen the …

The impact of osimertinib'line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

V Fuchs, L Roisman, W Kian, L Daniel, J Dudnik… - Lung Cancer, 2021 - cris.bgu.ac.il
Background: Resistance mechanisms following 1st line therapy with osimertinib in EGFR+
NSCLC have become focus of investigation. This retrospective study aims to deepen the …

The impact of osimertinib'line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance.

V Fuchs, L Roisman, W Kian, L Daniel… - Lung Cancer …, 2021 - europepmc.org
Background Resistance mechanisms following 1st line therapy with osimertinib in EGFR+
NSCLC have become focus of investigation. This retrospective study aims to deepen the …

The impact of osimertinib'line on clonal evolution in EGFRm NSCLC through NGS-based liquid biopsy and overcoming strategies for resistance

V Fuchs, L Roisman, W Kian, L Daniel, J Dudnik… - Lung Cancer, 2021 - cris.bgu.ac.il
Background: Resistance mechanisms following 1st line therapy with osimertinib in EGFR+
NSCLC have become focus of investigation. This retrospective study aims to deepen the …